The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

Researchers will use a blood-based biomarker developed in the VA Lung Precision Oncology Program to select best responders to the regimen.

The firm, which recently started a rolling BLA submission with the FDA for its Fabry disease gene therapy, will use the funds for general corporate expenses.

The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.